Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethyl eicosapentaenoic acid - Amarin

Drug Profile

Ethyl eicosapentaenoic acid - Amarin

Alternative Names: VAZKEPA; AMR-101; Eicosapentaenoic acid ethyl ester - Amarin; Eicosapentanoic acid ethyl ester; EPA-Vascepa; Ethyl eicosapentaenoate; Ethyl eicosopentaenoate; Ethyl icopenate; Ethyl-EPA; Icosapent ethyl - Amarin Corporation; Icosapentaenoic acid ethyl ester; LAX-101; LAX-101c; Miraxion™; Ultra-pure eicosapentaenoic acid; Ultra-pure EPA; Ultra-pure ethyl ecosapentaenoic acid; Ultra-pure ethyl EPA; Vascepa; VAZKEPA; Vazkepa

Latest Information Update: 15 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scarista
  • Developer Amarin Corporation; Biologix FZCo; Eddingpharm; HLS Therapeutics; University of Leeds; Yorkshire Cancer Research
  • Class Antidementias; Antidepressants; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Antivirals; Eicosanoids; Esters; Omega 3 fatty acids; Reactive oxygen species; Small molecules; Vascular disorder therapies
  • Mechanism of Action Diacylglycerol O-acyltransferase inhibitors; Phospholipase A2 inhibitors; Platelet aggregation inhibitors; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypertriglyceridaemia
  • Registered Cardiovascular disorders
  • Phase III Colorectal cancer; COVID 2019 infections; Liver metastases
  • Discontinued Huntington's disease; Major depressive disorder; Memory disorders; Parkinson's disease; Psychotic disorders

Most Recent Events

  • 09 May 2024 HLS Therapeutics completes a Product Listing Agreement (PLA) with the province of British Columbia, for the listing and public reimbursement of Vascepa
  • 03 Apr 2024 Amarin has patent pending from the 2033 patent family for ethyl eicosapentaenoic acid in Europe
  • 03 Apr 2024 Amarin has patent protection for ethyl eicosapentaenoic acid in Europe
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top